Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

MDS and Symptomatic Anemia.

Trial Name: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low-or Intermediate-1 Risk MDS and Symptomatic Anemia.

Protocol ID: E2905


  • Age > 18 yrs.
  • Patients must have documented diagnosis of MDS lasting at least three months or non-proliferative chronic myelomonocytic leukemia.
  • Patients must meet required laboratory values.
  • Patients must have failed treatment with an erythropoietic growth factor, or have a low probability of response to rhu-erythropoietin.
  • Women must not be pregnant or breast-feeding.
  • Women of childbearing potential and sexually active males must agree to use 2 methods of an accepted and effective method of contraception.
  • Patients must not have prior therapy with lenalidomide.
  • Patients must not have a diagnosis of uncontrolled seizure or uncontrolled hypertension.
  • Patients must not have MDS secondary to treatment with radiotherapy, chemotherapy, and/or immunotherapy for malignant or autoimmune disease.
  • Patients must not have prior history of malignancy other than MDS (except basal cell or squamous skin cell carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been free of disease for > 3 years.
  • Patients must not have a history of thrombo-embolic events within 3 years prior to study randomization.

Patients must not have a known allergic reaction to epoetin alfa (Procrit®) or human serum albumin.

Enrollment: About 236 people will take part in this study.



Taking part in this study may or may not make your health better. While doctors hope these drugs will be more useful against cancer compared to the usual treatment, there is no proof of this yet. We do know that the information from this study will help doctors learn more about these drugs as a treatment for cancer. This information could help future cancer patients.


These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Sep 18, 2009

Updated: Oct 16, 2014

« Return to Trials